Lathrop Investment Management Corp Purchases 2,513 Shares of Merck & Co., Inc. (NYSE:MRK)

Lathrop Investment Management Corp increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 48.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 7,677 shares of the company’s stock after acquiring an additional 2,513 shares during the period. Lathrop Investment Management Corp’s holdings in Merck & Co., Inc. were worth $646,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. grew its position in shares of Merck & Co., Inc. by 4.4% in the third quarter. Fox Run Management L.L.C. now owns 2,827 shares of the company’s stock valued at $238,000 after purchasing an additional 118 shares during the last quarter. First Command Bank grew its position in shares of Merck & Co., Inc. by 1.4% in the third quarter. First Command Bank now owns 8,599 shares of the company’s stock valued at $724,000 after purchasing an additional 118 shares during the last quarter. Allworth Financial LP grew its position in shares of Merck & Co., Inc. by 1.9% in the third quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock valued at $528,000 after purchasing an additional 119 shares during the last quarter. Stillwater Investment Management LLC grew its position in shares of Merck & Co., Inc. by 2.6% in the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock valued at $402,000 after purchasing an additional 120 shares during the last quarter. Finally, Southeast Asset Advisors Inc. grew its position in shares of Merck & Co., Inc. by 2.3% in the second quarter. Southeast Asset Advisors Inc. now owns 5,349 shares of the company’s stock valued at $449,000 after purchasing an additional 120 shares during the last quarter. Institutional investors and hedge funds own 75.02% of the company’s stock.

NYSE:MRK traded down $3.16 during trading hours on Tuesday, reaching $81.36. 7,451,321 shares of the company were exchanged, compared to its average volume of 6,929,566. The company has a market capitalization of $216.81 billion, a P/E ratio of 18.75, a P/E/G ratio of 1.98 and a beta of 0.53. Merck & Co., Inc. has a 1-year low of $66.10 and a 1-year high of $87.35. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The business has a 50 day moving average of $84.26 and a 200 day moving average of $82.33.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.06 earnings per share. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

In related news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

Several research firms have recently commented on MRK. Argus upped their target price on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. set a $96.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, October 10th. Societe Generale set a $105.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Bank of America began coverage on Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 target price on the stock. Finally, Mizuho reaffirmed a “buy” rating and issued a $97.00 target price on shares of Merck & Co., Inc. in a research report on Friday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus price target of $94.00.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: What is the Rule of 72?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.